Literature DB >> 12619035

Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.

Maryvonne Daveau1, Michel Scotte, Arnaud François, Cédric Coulouarn, Gilles Ros, Yveline Tallet, Martine Hiron, Marie-France Hellot, Jean-Philippe Salier.   

Abstract

A change in the balance between proliferation and apoptosis in the course of hepatocellular carcinoma (HCC) development and progression has been suspected. We wanted to identify related genes whose mRNA levels could provide markers of severity and prognosis after resection. The extent of cell apoptosis, proliferation, and differentiation was measured with a terminal deoxynucleotidyl transferase-mediated deoxyuridine 5-triphosphate-biotin nick-end labeling assay, and the Ki-67 index was determined in paired tumor and cirrhotic tissue samples from patients who had undergone HCC resection after diagnosis of hepatitis C-related or alcoholism-related cirrhosis. These patients included two groups with highly versus poorly differentiated tumor cells, and the latter was split into two subgroups of those with versus without early recurrence. The mRNA levels for various apoptosis-related or proliferation-related genes and those for the growth factor/receptor systems were measured by quantitative reverse transcriptase-polymerase chain reaction in paired tumor and cirrhotic liver samples from every patient, and some of the corresponding proteins were detected by immunohistochemistry. In all instances, protein expression was highly heterogeneous within groups and similar between groups. In contrast, some differences in mRNA level between tumor and cirrhotic tissues were quite informative. Low levels of hepatocyte growth factor and transforming growth factor alpha mRNAs were found concomitantly in highly differentiated tumors, whereas overexpression of mRNAs for the cognate receptors c-met and epidermal growth factor receptor were found in poorly differentiated tumors and primarily in patients with early tumor recurrence. These results argue for growth factor-dependent HCC development and provide novel and combined prognosis markers after HCC surgery. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619035     DOI: 10.1002/mc.10103

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  51 in total

Review 1.  c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.

Authors:  Daniel Delitto; Eva Vertes-George; Steven J Hughes; Kevin E Behrns; Jose G Trevino
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer.

Authors:  Alexander Huether; Michael Hopfner; Andreas P Sutter; Viola Baradari; Detlef Schuppan; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

3.  A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Authors:  Geoffrey I Shapiro; Stewart McCallum; Laurel M Adams; Laurie Sherman; Steve Weller; Suzanne Swann; Harold Keer; Dale Miles; Thomas Müller; Patricia Lorusso
Journal:  Invest New Drugs       Date:  2012-10-06       Impact factor: 3.850

4.  Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.

Authors:  Kesang Li; Suying Qian; Mengmeng Huang; Mengjie Chen; Ling Peng; Jianwen Liu; Wen Xu; Jianfen Xu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 5.  The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.

Authors:  Carmen Berasain; Matías A Avila
Journal:  J Gastroenterol       Date:  2013-12-10       Impact factor: 7.527

Review 6.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

7.  Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro.

Authors:  Gaelle del Castillo; Valentina M Factor; Margarita Fernández; Alberto Alvarez-Barrientos; Isabel Fabregat; Snorri S Thorgeirsson; Aránzazu Sánchez
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

8.  A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Thomas C C Yau; Riccardo Lencioni; Wattana Sukeepaisarnjaroen; Yee Chao; Chia-Jui Yen; Wirote Lausoontornsiri; Pei-Jer Chen; Theeranun Sanpajit; Aaron Camp; Donna S Cox; Robert C Gagnon; Yuan Liu; Kristen E Raffensperger; Diptee A Kulkarni; Howard Kallender; Lone Harild Ottesen; Ronnie T P Poon; Donald P Bottaro
Journal:  Clin Cancer Res       Date:  2016-11-07       Impact factor: 12.531

9.  Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection.

Authors:  Jun Cui; Bao-Wei Dong; Ping Liang; Xiao-Ling Yu; De-Jiang Yu
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

10.  Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi.

Authors:  Xiwen Liao; Chuangye Han; Wei Qin; Xiaoguang Liu; Long Yu; Sicong Lu; Zhiwei Chen; Guangzhi Zhu; Hao Su; Zengnan Mo; Xue Qin; Tao Peng
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.